Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AMPH
stocks logo

AMPH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
190.48M
+2.12%
0.922
+0.23%
169.00M
-0.9%
0.805
+8.78%
173.00M
-0.81%
0.800
-5.88%
Estimates Revision
The market is revising Upward the revenue expectations for Amphastar Pharmaceuticals, Inc. (AMPH) for FY2025, with the revenue forecasts being adjusted by 0.16% over the past three months. During the same period, the stock price has changed by -7.72%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.16%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.57%
In Past 3 Month
Stock Price
Go Down
down Image
-7.72%
In Past 3 Month
Wall Street analysts forecast AMPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMPH is 29.50 USD with a low forecast of 25.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast AMPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMPH is 29.50 USD with a low forecast of 25.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 27.150
sliders
Low
25.00
Averages
29.50
High
34.00
Current: 27.150
sliders
Low
25.00
Averages
29.50
High
34.00
BofA
Neutral
maintain
$28 -> $32
2025-08-26
Reason
BofA
Price Target
$28 -> $32
2025-08-26
maintain
Neutral
Reason
BofA raised the firm's price target on Amphastar to $32 from $28 and keeps a Neutral rating on the shares after increasing near-term forecasts to reflect the recent generic Venofer approval. Generic Venofer "looks like a good, but not great, generic product due to competitive dynamics at market formation," the analyst tells investors.
Needham
Serge Belanger
Hold
to
Buy
upgrade
$36
2025-08-12
Reason
Needham
Serge Belanger
Price Target
$36
2025-08-12
upgrade
Hold
to
Buy
Reason
Needham analyst Serge Belanger upgraded Amphastar to Buy from Hold with a $36 price target.
Needham
Hold
to
Buy
upgrade
$36
2025-08-12
Reason
Needham
Price Target
$36
2025-08-12
upgrade
Hold
to
Buy
Reason
Needham upgraded Amphastar (APMH) to Buy from Hold with a $36 price target. The company's AMP-002 is an iron sucrose injection product that received FDA approval as an equivalent to Venofer, a $515M annual sales product, the analyst tells investors in a research note. The firm says the only downside to the approval is an equivalent generic product by Viatris (VTRS) was also approved. Needham cites valuation for the upgrade of Amphastar and believes AMP-002 sales should help the company at least meet growth expectations for 2025 and 2026.
Piper Sandler
Neutral
downgrade
$30 -> $25
2025-08-08
Reason
Piper Sandler
Price Target
$30 -> $25
2025-08-08
downgrade
Neutral
Reason
Piper Sandler lowered the firm's price target on Amphastar to $25 from $30 and keeps a Neutral rating on the shares following quarterly results. The firm cites tempered generics sales estimates and lower gross margins. Competitive headwinds remain a challenge, Piper adds.
JPMorgan
Overweight -> Neutral
downgrade
$45 -> $30
2025-05-12
Reason
JPMorgan
Price Target
$45 -> $30
2025-05-12
downgrade
Overweight -> Neutral
Reason
JPMorgan downgraded Amphastar to Neutral from Overweight with a price target of $30, down from $45. The company has seen continued setbacks on the pipeline front, the analyst tells investors in a research note. The firm says that while Amphastar's generic business remains better positioned than some peers, both glucagon and epinephrine are eroding faster than the Street was expecting. As such, it sees better opportunities elsewhere in the space.
Wells Fargo
Cerena Chen
Overweight
downgrade
$40 -> $35
2025-05-08
Reason
Wells Fargo
Cerena Chen
Price Target
$40 -> $35
2025-05-08
downgrade
Overweight
Reason
Wells Fargo analyst Cerena Chen lowered the firm's price target on Amphastar to $35 from $40 and keeps an Overweight rating on the shares. The firm says that continued expectations for 2 launches this year despite recent CRLs is reassuring though it notes sales contribution would be more meaningful in 2026. Good Baqsimi and Primatene growth make Wells less concerned about competitive pressure elsewhere.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Amphastar Pharmaceuticals Inc (AMPH.O) is 7.97, compared to its 5-year average forward P/E of 14.38. For a more detailed relative valuation and DCF analysis to assess Amphastar Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
14.38
Current PE
7.97
Overvalued PE
18.94
Undervalued PE
9.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
8.57
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
10.35
Undervalued EV/EBITDA
6.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.56
Current PS
0.00
Overvalued PS
3.20
Undervalued PS
1.93
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 4073.82% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 4073.82% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

AMPH News & Events

Events Timeline

(ET)
2025-11-06
16:22:41
Amphastar announces Q3 adjusted earnings per share of 93 cents, surpassing consensus estimate of 83 cents.
select
2025-08-12 (ET)
2025-08-12
06:48:17
Amphastar announced FDA approval of iron sucrose injection
select
2025-07-23 (ET)
2025-07-23
08:08:48
Amphastar sees Q3 adjusted EPS 77c-79c, consensus 69c
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-28NASDAQ.COM
Amphastar (AMPH) Third Quarter 2025 Earnings Call Summary
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
3.0
11-11NASDAQ.COM
Breaking Down the Components: IJR Aims for $140

  • ETF Analysis: The iShares Core S&P Small-Cap ETF (IJR) has an implied analyst target price of $139.64, indicating a potential upside of 17.18% from its current trading price of $119.17.

  • Notable Holdings: Key underlying holdings with significant upside potential include Dream Finders Homes Inc (DFH), Amphastar Pharmaceuticals Inc (AMPH), and Rogers Corp. (ROG), with expected price increases of 27.16%, 24.43%, and 23.36% respectively.

  • Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets may lead to downgrades if they do not align with recent developments.

  • Investor Research: Investors are encouraged to conduct further research to assess the validity of analyst targets and their alignment with current market conditions and company performance.

[object Object]
Preview
4.0
11-11NASDAQ.COM
Daily Upgrade Report for Validea's Peter Lynch Strategy - November 11, 2025

  • Amphastar Pharmaceuticals: The stock rating increased from 56% to 74% based on its fundamentals and valuation, indicating a growing interest in this small-cap value stock in the Biotechnology & Drugs industry.

  • CECO Environmental Corp: The rating for this small-cap growth stock rose from 72% to 87%, reflecting strong fundamentals and valuation in the Misc. Capital Goods industry, suggesting significant interest.

  • Crawford & Company: The stock rating improved dramatically from 0% to 74%, highlighting a positive shift in its fundamentals and valuation within the Insurance (Miscellaneous) industry.

  • Republic Bancorp Inc: The rating increased from 61% to 81%, indicating a favorable assessment of its fundamentals and valuation as a small-cap value stock in the Money Center Banks industry.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Amphastar Pharmaceuticals Inc (AMPH) stock price today?

The current price of AMPH is 27.15 USD — it has decreased -1.56 % in the last trading day.

arrow icon

What is Amphastar Pharmaceuticals Inc (AMPH)'s business?

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.

arrow icon

What is the price predicton of AMPH Stock?

Wall Street analysts forecast AMPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMPH is 29.50 USD with a low forecast of 25.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Amphastar Pharmaceuticals Inc (AMPH)'s revenue for the last quarter?

Amphastar Pharmaceuticals Inc revenue for the last quarter amounts to 191.84M USD, increased 0.33 % YoY.

arrow icon

What is Amphastar Pharmaceuticals Inc (AMPH)'s earnings per share (EPS) for the last quarter?

Amphastar Pharmaceuticals Inc. EPS for the last quarter amounts to 0.36 USD, decreased -53.85 % YoY.

arrow icon

What changes have occurred in the market's expectations for Amphastar Pharmaceuticals Inc (AMPH)'s fundamentals?

The market is revising Upward the revenue expectations for Amphastar Pharmaceuticals, Inc. (AMPH) for FY2025, with the revenue forecasts being adjusted by 0.16% over the past three months. During the same period, the stock price has changed by -7.72%.
arrow icon

How many employees does Amphastar Pharmaceuticals Inc (AMPH). have?

Amphastar Pharmaceuticals Inc (AMPH) has 2028 emplpoyees as of December 05 2025.

arrow icon

What is Amphastar Pharmaceuticals Inc (AMPH) market cap?

Today AMPH has the market capitalization of 1.25B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free